Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 18/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 17/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3373106 | 1.00 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL3373109 | 1.00 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL1422669 | 0.79 | SLC6A4 (0.36) | SLC6A4SLC6A2SLC6A3HTR2A | |
| SCHEMBL3401884 | 0.79 | SLC6A4 (0.38) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL3401890 | 0.79 | SLC6A4 (0.38) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL1422672 | 0.79 | SLC6A4 (0.36) | SLC6A4SLC6A2SLC6A3HTR2A | |
| SCHEMBL13067285 | 0.79 | SLC6A2 (0.47) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3372443 | 0.78 | ALDH1A1 (0.46) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6305830 | 0.78 | ALDH1A1 (0.46) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1312619 | 0.78 | ALDH1A1 (0.46) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6566538-B1 | Preparation of 5-(aryloxymethyl)-g-butyrolactone derivatives | MILLENNIUM PHARMACEUTICALS, INC. | 2003-05-20 | — | — | US | disclosed |
| US-6433197-B1 | REACTING ARYLHYDROXY COMPOUND AND AN EPOXY COMPOUND TO FORM AN EPOXY-ARYL ETHER; REACTING EPOXY-ARYL ETHER WITH ACTIVE METHYLENE COMPOUND TO FORM A LACTONE; REDUCING TO PROVIDE HYDROXY-SUBSTITUTED TETRAHYDROFURAN | MILLENNIUM PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| EP-1115702-A4 | SUBSTITUTED NITROGEN AND SULFUR ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | MILLENNIUM PHARM INC (US) | 2002-04-17 | — | — | EP | disclosed |
| US-20020040154-A1 | Substituted oxygen alicyclic compounds, including methods for synthesis thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2002-04-04 | — | — | US | disclosed |
| EP-1115702-A1 | SUBSTITUTED NITROGEN AND SULFUR ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000001670-A1 | SUBSTITUTED NITROGEN AND SULFUR ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | LEUKOSITE, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040154-A1 | Substituted oxygen alicyclic compounds, including methods for synthesis thereof | OXER1, COX6C, MT-CO2 | SLC6A4 4263/4885SLC6A2 4075/4885SLC6A3 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.